Strados Labs

04/02/2026

The RESP® Biosensor was developed to fit naturally into daily life—wireless, discreet, water-resistant, and secured with gentle 3M Tegaderm™ for comfort and ease of wear. With a 24+ hour battery life and cloud-based sync, RESP® enables continuous, passive monitoring without interrupting routines.

Patients and families consistently share positive feedback—many say they feel safer wearing RESP® and often forget it’s even there. That comfort translates to lower burden, more authentic data, and strong adherence in clinical trials.

Visit our website to learn more: https://stradoslabs.com/

03/31/2026

COPD affects hundreds of millions of people worldwide, and its impact reaches far beyond lung function alone.

Stories from patients and caregivers show how COPD influences daily routines, independence, emotional wellbeing, and family life. Despite how common and serious the disease is, it’s still often underdiagnosed or misunderstood, which can delay support and increase the burden on both patients and those caring for them.

These perspectives are a reminder that understanding respiratory disease requires more than clinic-based measurements. Recognizing how symptoms evolve day to day — and how they influence daily function — helps clinicians and researchers better assess disease burden, progression, and treatment response in ways that reflect patients’ lived experience.

More from Sanofi: https://bit.ly/46iw2zn

Despite its prevalence and severity, COPD remains underdiagnosed and misunderstood, compounding its impact on patients and their caregivers.

03/26/2026

A strong step forward for digital endpoints and an exciting moment for the industry.

A new paper in Nature Reviews Drug Discovery highlights what many of us have been working toward: a clear, quantified business case for the systematic adoption of digital endpoints in clinical trials.

The findings are compelling:
• Reduced trial timelines by 3–5 months
• Smaller study sizes
• Significant ROI — up to 14–22× in Phase III

At Strados Labs, we’re proud to have contributed to this effort through our participation in the Digital Medicine Society (DiMe) project, Building the Business Case for Digital Endpoints.

As sponsors look to innovate under increasing R&D pressure, the opportunity is clear: those who adopt early and systematically will not only capture value, but help define the future of clinical development.

Read the full article here: https://doi.org/10.1038/d41573-026-00033-5

Discover the world’s best science and medicine | Nature.com

03/25/2026

Why Measure Cough and Lung Sounds in Respiratory Trials?

In our latest blog by Matthew McCarty, Chief Commercial Officer at Strados Labs, we explore how objective cough and lung sound monitoring can offer meaningful strategic value — even in indications beyond chronic cough.

When combined with traditional endpoints and patient-reported outcomes, these measures can strengthen label claims, help differentiate therapies in competitive markets, and provide a more complete view of treatment effect in daily life.

There’s also a growing financial case. Modeling studies suggest digital endpoints may improve measurement precision, reduce variability, and support stronger development decisions — with the potential to increase expected net present value and return on investment, particularly in later-stage trials.

Read the full blog! https://lnkd.in/g6CnfyQG

03/23/2026

What an energizing 2 days at BICC!

We were extremely proud to join the global community of clinicians, researchers, and industry leaders focused on finding solutions for the millions of people living with chronic cough.

Throughout the conference, it was clear that:
• Interest in objective, continuous cough monitoring continues to grow
• There is increasing focus on moving beyond frequency alone
• Digital endpoints are becoming a more important part of study design and decision-making

We’re excited to continue these conversations and build on the momentum coming out of BICC!

03/19/2026

Personalized self-management is becoming an increasingly important part of chronic respiratory care.

Tailored action plans, patient education, and ongoing support can help patients recognize symptom changes earlier and respond before exacerbations worsen. When people have better visibility into how their condition shifts day to day, they’re more likely to stay engaged in care and maintain control over time. Still, access to consistent guidance and monitoring isn’t always equal, which can influence outcomes.

This growing focus on personalized management also reinforces the importance of understanding respiratory symptoms between clinic visits. Reliable insight into cough patterns and airway activity can help translate care plans into measurable trends — supporting earlier intervention, stronger clinical evaluation, and a clearer picture of disease impact outside the clinic.

Medscape shares more on this approach to chronic respiratory care: https://www.medscape.com/viewarticle/personalized-self-management-empowers-patients-chronic-2025a1000rxb

The respiratory medical community is moving toward shared decision-making in self-managing chronic respiratory disease, but implementation remains challenging for most people with limited access to basic meds.

03/18/2026

BICC is in just a few days! If you’re attending, don’t miss our upcoming presentation:

Beyond cough frequency: applications of a multimodal acoustic monitoring platform
Presented by Tom deLaubenfels, Director of Data Science at Strados Labs
March 21 | 9:30–9:45 AM (GMT+1)

As interest in objective cough monitoring continues to grow, this session will explore how multimodal acoustic data can go beyond simple cough counts — offering deeper insights into cough characteristics, patterns, and broader respiratory signals.

For sponsors and researchers, this opens the door to:
• More comprehensive measures of cough burden
• Improved understanding of treatment response
• New opportunities for exploratory and digital endpoints

If you’re at BICC, we’d love to connect. Feel free to reach out or find us during the meeting.

03/12/2026

What are the "big three" causes of chronic cough?

Chronic cough, typically defined as lasting more than eight weeks, is most often linked to three conditions: postnasal drip, asthma, and gastroesophageal reflux disease (GERD). Mucus drainage can trigger the cough reflex, asthma may present primarily as cough even without wheezing, and reflux can irritate the airway when stomach acid reaches the throat. Identifying the underlying driver is key to choosing the right treatment approach.

Because similar symptoms can arise from very different mechanisms, careful evaluation of cough patterns and progression can provide important clinical insight — and help inform both patient management and respiratory research.

Learn more from Houston Methodist: https://bit.ly/4aqezaz

Chronic cough is considered a lung disorder after eight weeks of persistent coughing. Contact Houston Methodist to learn more about the causes, symptoms, and treatment of chronic coughing. Find your pulmonologist at Houston Methodist.

03/10/2026

We’re looking forward to attending the Barcelona International Cough Conference (BICC), taking place March 20–21, 2026 in Barcelona and online!

BICC brings together clinicians, researchers, and industry leaders focused on advancing the science and clinical understanding of cough. Our Chief Commercial Officer Matthew McCarty and Director of Data Science Tom deLaubenfels will be attending on behalf of Strados.

Tune into our session on March 21st from 9:30 am - 9:45: Beyond cough frequency: applications of a multimodal acoustic monitoring platform, presented by Dr. deLaubenfels.

If you’ll be at BICC, we’d love the opportunity to connect and continue the conversation around objective measurement and digital approaches in respiratory research.

Learn more about the conference:
https://www.bicc.es/BICC24/en/home-en

03/04/2026

We're hiring!

As adoption of digital respiratory endpoints continues to grow in clinical research, we're expanding our commercial team.

We’re looking for a Director, Business Development – Respiratory Clinical Solutions to help deepen strategic partnerships with pharmaceutical and biotech sponsors and support multi-program collaborations across respiratory clinical trials.

This role will work closely with scientific, clinical, and operational stakeholders to advance the use of objective respiratory measurements in drug development.

If you have experience in respiratory medicine, pulmonary clinical research, or clinical trial solutions, we’d love to connect.

Know someone who might be a great fit? Feel free to share the opportunity.

🔗 Learn more and apply: https://www.linkedin.com/jobs/view/4379931410/

03/03/2026

Not all asthma patients present with wheeze or breathlessness.

Cough-variant asthma (CVA) is a form of asthma in which persistent cough may be the primary — and sometimes only — symptom, even without wheezing or shortness of breath. Despite this atypical presentation, CVA can involve airway hyperresponsiveness and inflammation similar to traditional asthma, making early recognition and treatment important.

For respiratory studies, presentations like CVA illustrate how meaningful symptoms can be overlooked when assessments rely only on episodic clinic visits or patient self-reporting. Objective cough measurement can help provide quantifiable evidence of symptom patterns and treatment response, supporting stronger endpoint strategies and a clearer understanding of disease impact.

Learn more in the Journal of Allergy and Clinical Immunology: https://www.jaci-inpractice.org/article/S2213-2198(24)01170-X/abstract

02/26/2026

Asthma affects more than 300 million people globally and remains a leading cause of pediatric emergency department visits and missed school days. Yet much of asthma management still relies on episodic assessments and patient-reported outcomes that can miss important insights.

The RESP® Platform is designed to support remote asthma monitoring by capturing objective, real-world measures of cough, wheeze, and breathing patterns—complementing pulmonary function tests and patient self-reporting to build a more complete picture of disease burden.

Learn more about RESP® for Asthma:
https://stradoslabs.com/therapeutic-areas-wearable-asthma-monitoring-device/